Anti-interleukin-5 antibody therapy in eosinophilic diseases (Q36438486)

14 August 2017

1 reference

title

Anti-interleukin-5 antibody therapy in eosinophilic diseases (English)

1 reference

14 August 2017

0 references

Hans-Uwe Simon

3

0 references

author name string

Dagmar Simon

series ordinal

1

1 reference

14 August 2017

Lasse R Braathen

series ordinal

2

1 reference

14 August 2017

publication date

1 January 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

72

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

287-292

1 reference

The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract.

14 August 2017

cites work

1 reference

The role of eosinophils in host defense against helminth parasites

21 January 2018

1 reference

Mechanisms of eosinophil-associated inflammation

21 January 2018

1 reference

IL-5-induced airway eosinophilia--the key to asthma?

21 January 2018

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

21 January 2018

1 reference

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

The trials and tribulations of IL-5, eosinophils, and allergic asthma

21 January 2018

1 reference

Verdict in the case of therapies versus eosinophils: the jury is still out.

21 January 2018

1 reference

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

21 January 2018

1 reference

Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma

21 January 2018

1 reference

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge

21 January 2018

1 reference

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process

21 January 2018

1 reference

Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alph

21 January 2018

1 reference

A role for eosinophils in airway remodelling in asthma

21 January 2018

1 reference

The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness

21 January 2018

1 reference

Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor alpha chain-deficient mice

21 January 2018

1 reference

Effect of a novel interleukin-5 receptor antagonist, YM-90709 (2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline), on antigen-induced airway inflammation in BN rats

21 January 2018

1 reference

Hypereosinophilic syndrome: case presentation and update

21 January 2018

1 reference

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

21 January 2018

1 reference

Eosinophils and atopic dermatitis

21 January 2018

1 reference

Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration.

21 January 2018

1 reference

Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment

21 January 2018

1 reference

Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment

21 January 2018

1 reference

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

21 January 2018

1 reference

Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin

21 January 2018

1 reference

Eosinophilic gastrointestinal disorders (EGID).

21 January 2018

1 reference

Eosinophilic esophagitis: red on microscopy, white on endoscopy.

21 January 2018

1 reference

Eosinophilic esophagitis: asthma of the esophagus?

21 January 2018

1 reference

Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases

21 January 2018

1 reference

IL-5 promotes eosinophil trafficking to the esophagus.

21 January 2018

1 reference

Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism

21 January 2018

1 reference

Eosinophilopoiesis in A Murine Model of Allergic Airway Eosinophilia: Involvement of Bone Marrow IL-5 and IL-5 Receptor

21 January 2018

1 reference

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000091326

1 reference

14 August 2017

1 reference